<i>APOE</i> Genotypes Modulate Inflammation Independently of Their Effect on Lipid Metabolism
The association between <i>APOE</i> genotypes and cardiovascular disease (CVD) is partially mediated by LDL-cholesterol concentration but persists after adjusting for lipid levels and other cardiovascular risk factors. Data from the Aragon Workers Health Study (AWHS) (n = 4159) and the L...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/21/12947 |
| Summary: | The association between <i>APOE</i> genotypes and cardiovascular disease (CVD) is partially mediated by LDL-cholesterol concentration but persists after adjusting for lipid levels and other cardiovascular risk factors. Data from the Aragon Workers Health Study (AWHS) (n = 4159) and the Lipid Unit at the Hospital Universitario Miguel Servet (HUMS) (n = 3705) were used to investigate the relationship between C-reactive protein (CRP) levels and <i>APOE</i> genotype. Lipoprotein particle and GlycA concentrations were analyzed in a subsample from AWHS. <i>APOE</i> genotyping was carried out by the Sanger method in both cohorts. <i>APOE4</i> carriers had significantly lower levels of CRP than <i>APOE3</i> carriers. Furthermore, <i>APOE</i>4 carriers had cholesterol-enriched LDL particles compared to <i>APOE2</i> carriers. <i>APOE4</i> carriers also had higher concentrations of small, medium, and large LDL particles. CRP levels were not associated with lipoprotein particle number, size, or composition. GlycA levels were not associated with <i>APOE</i> genotypes. However, GlycA levels were significantly associated with the size and the amount of cholesterol contained in HDL, VLDL, and LDL particles. <i>APOE</i> genotype influences CRP concentration regardless of lipid profile. <i>APOE2</i> carriers showed the highest CRP levels, followed by <i>APOE3</i> and <i>APOE4</i>. A more atherogenic lipid profile, but not inflammatory markers could partly explain the higher CVD risk observed in <i>APOE4</i> carriers. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |